Cells,
Год журнала:
2023,
Номер
12(17), С. 2204 - 2204
Опубликована: Сен. 4, 2023
Genomic-based
precision
medicine
has
not
only
improved
tumour
therapy
but
also
shown
its
weaknesses.
Genomic
profiling
and
mutation
analysis
have
identified
alterations
that
play
a
major
role
in
sarcoma
pathogenesis
evolution.
However,
they
been
sufficient
predicting
vulnerability
advancing
treatment.
The
relative
rarity
of
sarcomas
the
genetic
heterogeneity
between
subtypes
stand
way
gaining
statistically
significant
results
from
clinical
trials.
Personalized
three-dimensional
models
reflect
specific
histologic
subtype
are
emerging
as
functional
assays
to
test
anticancer
drugs,
complementing
genomic
screening.
Here,
we
provide
an
overview
current
target
for
discuss
based
on
3D
that,
by
recapitulating
molecular
pathways
microenvironment,
may
predict
patient
response
treatments.
This
approach
opens
new
avenues
improve
when
pathway
guide
choice
most
promising
Furthermore,
aspects
culture
need
be
improved,
such
standardisation
growth
conditions
definition
vitro
responses
can
used
cut-off
implementation.
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(4), С. 1542 - 1542
Опубликована: Фев. 12, 2025
Chondrosarcoma
(CS),
the
second
most
common
malignant
bone
tumor
after
osteosarcoma,
accounts
for
20-30%
of
all
tumors.
It
mainly
affects
adults,
middle-aged,
and
elderly
people.
The
CS
family
includes
various
entities
displaying
peculiar
biological,
genetic,
epigenetic
characteristics
clinical
behaviors.
Conventional
is
subtype.
High-grade,
dedifferentiated,
mesenchymal
CS,
as
well
unresectable
metastatic
exhibit
poor
prognoses
due
to
their
intrinsic
resistance
radiotherapy
chemotherapy,
underscoring
urgent
need
novel
therapeutic
strategies.
research
dealing
with
several
challenges.
Experimental
studies
can
rely
on
animal
patient-derived
models,
but
paucity
representative
near-patient
preclinical
models
has
hampered
predictive
drug
screening
research.
This
review
describes
main
molecular
features
subtypes,
discussing
recent
data
genetic
alterations
mechanisms
involved
in
pathogenesis
progression.
provides
an
overview
current
vitro
vivo
discusses
advantages
limitations,
highlights
efforts
development
new
targeted
therapies
against
dependencies,
including
IDH1/2
mutations,
NAD+
dependency,
SIRT1-HIF-2α
axis,
or
exploring
DR5
targeting,
antiangiogenic
therapies,
drugs,
immunological
approaches.
All
such
strategies,
combination
advanced
modeling
personalized
multi-omic
profiling,
hold
promise
improving
survival
patients
CS.
Research Square (Research Square),
Год журнала:
2025,
Номер
unknown
Опубликована: Май 7, 2025
Abstract
CIC::DUX4
sarcoma
(CDS)
is
a
highly
aggressive
malignancy
with
limited
therapeutic
options.
Here,
we
present
doxycycline-inducible
chimeric
mouse
model
and
cancer
line
derived
from
it,
imChCDS,
that
faithfully
recapitulates
the
molecular,
histological,
immunological
features
of
human
CDS.
We
demonstrate
expression
alone
sufficient
to
drive
tumorigenesis
in
permissive
lineages
soft
connective
tissues.
The
imChCDS
cell
retains
transcriptional
footprint
its
mesenchymal
origin,
develops
tumors
immunocompetent
hosts,
exhibits
clear
dependency
on
P300/CBP
co-activators.
Notably,
identify
CIC::DUX4-mediated
suppression
MHC
class
I
(MHCI)
as
key
mechanism
CDS
immune
evasion.
Inactivation
restores
MHCI
expression,
triggers
robust
anti-tumor
responses,
leads
tumor
regression.
Together,
these
models
offer
versatile
physiologically
relevant
platform
investigate
pathogenesis,
unravel
evasion
mechanisms,
evaluate
emerging
strategies,
including
those
targeting
CIC::DUX4/P300/CBP
oncogenic
axis.
Biomolecules,
Год журнала:
2025,
Номер
15(5), С. 693 - 693
Опубликована: Май 10, 2025
Precision
oncology
is
becoming
a
mainstay
in
the
standard
of
care
for
cancer
patients.
Recent
technological
advancements
have
significantly
lowered
cost
various
tumor
profiling
approaches,
broadening
reach
molecular
diagnostics
and
improving
patient
access
to
precision
oncology.
In
parallel,
drug
development
discovery
pipelines
continue
evolve,
driving
targeted
therapeutic
options
forward.
Yet,
not
all
patients
harboring
actionable
alterations
respond
these
interventions,
existing
therapies
do
cover
entire
spectrum
potential
targets.
this
review,
we
examine
current
suite
omics
technologies
employed
clinical
settings
underscore
their
roles
deepening
our
understanding
biology
optimizing
stratification
treatments.
We
also
highlight
relevant
trials
share
own
experiences
using
multi-omics
data
within
board
framework.
Finally,
discuss
areas
future
exploration
aimed
at
propelling
new
heights.
Advanced Science,
Год журнала:
2025,
Номер
unknown
Опубликована: Июнь 4, 2025
Abstract
As
one
of
the
most
advanced
in
vitro
drug
screening
platforms,
tumor
organoids
require
accurate
pharmacosensitivity
assessments
to
ensure
reliable
results.
However,
achieving
volume
assessment
these
3D
organoid
models
remains
a
challenge
traditional
processes.
Here,
label‐free
photoacoustic
imaging
(LFOPI)
system
is
introduced
for
high‐resolution
organoids.
The
capabilities
LFOPI
are
evaluated
by
monitoring
structural
transformations
melanoma
further
employed
volumetric
Drug
with
cisplatin
and
temozolomide
reveal
that
LFOPI‐based
data
correlates
more
strongly
viability
trends
(0.8627
0.9069)
than
diameter‐based
methods
(0.8190
0.7849).
Additionally,
immunotherapy
demonstrates
capability
precisely
assess
volumes
irregularly
shaped
This
provides
promising
method
personalized
treatment.
Cell Reports Methods,
Год журнала:
2024,
Номер
4(5), С. 100772 - 100772
Опубликована: Май 1, 2024
Localized
cutaneous
neurofibromas
(cNFs)
are
benign
tumors
that
arise
in
the
dermis
of
patients
affected
by
neurofibromatosis
type
1
syndrome.
cNFs
lesions:
they
do
not
undergo
malignant
transformation
or
metastasize.
Nevertheless,
can
cover
a
significant
proportion
body,
with
some
individuals
developing
hundreds
to
thousands
lesions.
cause
pain,
itching,
and
disfigurement
resulting
substantial
socio-emotional
repercussions.
Currently,
surgery
laser
desiccation
sole
treatment
options
but
may
result
scarring
potential
regrowth
from
incomplete
removal.
To
identify
effective
systemic
therapies,
we
introduce
an
approach
establish
screen
cNF
organoids.
We
optimized
conditions
support
ex
vivo
growth
genomically
diverse
cNFs.
Patient-derived
organoids
closely
recapitulate
cellular
molecular
features
parental
as
measured
immunohistopathology,
methylation,
RNA
sequencing,
flow
cytometry.
Our
organoid
platform
enables
rapid
screening
compounds
patient-
tumor-specific
manner.
